Elicio Therapeutics, Inc. (ELTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Elicio Therapeutics reported revenue of $0. Net income was -$39.6M, or -$2.58 per diluted share. Operating activities generated -$37.0M of cash, leaving -$37.0M of free cash flow. At fiscal year end, Elicio Therapeutics held $25.9M in total assets against $24.2M in total liabilities, including $18.6M of cash and equivalents.
Open the full interactive Elicio Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Elicio Therapeutics Key Stats
| Share Price | $1.77 |
|---|---|
| Market Cap | $34.1M |
| 52-Week Range | $1.77 – $14.85 |
| Shares Outstanding | 19.2 million (basic, 2026 Q2) |
Elicio Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $28.3M | $2.3M | $0 | $0 | $0 |
| Cost of Goods Sold | $67.6M | $41.9M | — | — | — |
| Gross Profit | $27.9M | $2.3M | — | — | — |
| Operating Income | -$39.3M | -$39.6M | -$35.7M | -$45.0M | -$37.7M |
| Pre-Tax Income | -$54.6M | -$38.8M | -$35.2M | -$51.9M | -$39.6M |
| Income Tax | $0 | $11,000 | $0 | $0 | $0 |
| Net Income | -$54.6M | -$38.8M | -$35.2M | -$51.9M | -$39.6M |
| Diluted EPS | -$19.30 | -$12.90 | -$6.96 | -$4.25 | -$2.58 |
Elicio Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$10.1M | -$7.7M | -$11.8M | -$8.2M |
| Diluted EPS | -$0.60 | -$0.50 | -$0.65 | -$0.43 |
Elicio Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $88.8M | $50.5M | $12.9M | $17.6M | $18.6M |
| Current Assets | $91.2M | $51.4M | $16.3M | $20.7M | $19.3M |
| Total Assets | $96.5M | $52.8M | $27.1M | $28.2M | $25.9M |
| Current Liabilities | $11.3M | $6.4M | $9.8M | $11.5M | $8.1M |
| Total Long-Term Debt | — | — | — | $20.0M | $10.0M |
| Total Liabilities | $15.0M | $9.0M | $15.8M | $39.5M | $24.2M |
| Shareholders' Equity | $81.5M | $43.8M | $11.4M | -$11.3M | $1.6M |
Elicio Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$52.6M | -$38.4M | -$32.7M | -$37.1M | -$37.0M |
| Cash From Investing | -$382,000 | $0 | -$32,000 | -$84,000 | -$16,000 |
| Cash From Financing | $107.2M | -$60,000 | $38.6M | $42.3M | $36.7M |
| Free Cash Flow | -$53.0M | -$38.4M | -$32.8M | -$37.2M | -$37.0M |
Figures from Elicio Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Elicio Therapeutics financials page for every line item.
Elicio Therapeutics Company Profile
| Ticker | ELTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001601485 |
Frequently Asked Questions
What was Elicio Therapeutics' revenue in fiscal 2025?
Elicio Therapeutics (ELTX) reported revenue of $0 for fiscal 2025.
What is Elicio Therapeutics' annual revenue history?
Elicio Therapeutics' annual revenue by fiscal year: 2021: $28.3M; 2022: $2.3M; 2023: $0; 2024: $0; 2025: $0.
What was Elicio Therapeutics' net income in fiscal 2025?
Elicio Therapeutics reported net income of -$39.6M for fiscal 2025.
What was Elicio Therapeutics' earnings per share (EPS) in fiscal 2025?
Elicio Therapeutics' diluted EPS was -$2.58 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Elicio Therapeutics generate in fiscal 2025?
Elicio Therapeutics generated -$37.0M of free cash flow in fiscal 2025.
What was Elicio Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Elicio Therapeutics reported revenue of $0.
How much debt does Elicio Therapeutics have?
Elicio Therapeutics reported $10.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Elicio Therapeutics are outstanding?
Elicio Therapeutics reported a weighted average of 19.2 million basic shares outstanding in 2026 Q2.
What is Elicio Therapeutics' market cap?
Based on its latest closing price, Elicio Therapeutics (ELTX) has a market capitalization of about $34.1M.
When does Elicio Therapeutics' fiscal year end?
Elicio Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Elicio Therapeutics headquartered?
Elicio Therapeutics lists its business address in Boston, Massachusetts in its SEC filings.